Psychemedics Corporation (PMDI)

Market Cap	14.69M +9.2%
Revenue (ttm)	19.69M -10.9%
Net Income	-1.86M
EPS	-0.32
Shares Out	6.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.400
Previous Close	2.400
Day's Range	2.400 - 2.400
52-Week Range	1.330 - 2.500
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	May 26, 2026

About Psychemedics

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; syntheti...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 101
• Stock Exchange: OTCMKTS
• Ticker Symbol: PMDI

Financial Performance

In 2024, Psychemedics's revenue was $19.69 million, a decrease of -10.92% compared to the previous year's $22.10 million. Losses were -$1.86 million, -55.20% less than in 2023.